Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

GlaxoSmithKline to Make Clinical Trial Data Available to Other Researchers

October 12, 2012

GlaxoSmithKline (GSK) CEO Andrew Witty "said on Thursday detailed data from its clinical trials would be made available to other researchers," Reuters reports, adding, "That would include anonymized patient-level results that sit behind clinical trials of approved and failed drugs" (Hirschler, 10/11). In a speech to the Wellcome Trust in London on Thursday, Witty said that "openness to the public and active collaboration with scientists and firms outside GSK are essential to finding new drugs to treat the diseases plaguing the world, from novel antibiotics to cures for malaria and tuberculosis," the Guardian writes (Boseley, 10/10). "The initiative will enable researchers to examine the data more closely or combine data from different studies to carry out further research and learn more about how medicines work, the company said," according to the Wall Street Journal (Falconi, 10/11).

"Researchers contacted about the plan on Wednesday expressed a mix of enthusiasm and skepticism, citing the recent $3 billion settlement by GlaxoSmithKline with the federal government over charges that the company had misrepresented trial data for popular drugs like Avandia and Paxil," the New York Times writes. "Still, the company is taking a step in the right direction, the researchers said, and might set a precedent in an industry that could use more transparency," the newspaper notes, adding, "Whether more disclosure might lead to safer, more effective drugs remains to be seen" (Thomas, 10/11). "Witty also pledged to seek publication of the results of all clinical trials that evaluate Glaxo's medicines -- regardless of what they say -- to peer-reviewed scientific journals," the Wall Street Journal notes (10/11).

Back to other news for October 2012


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More News and Info on Clinical Trials
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement